A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice

Middle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that has been causing severe and fatal acute respiratory illnesses in humans since its outbreak in 2012, has raised public fear worldwide. The development of prophylactics and therapeutics is urgently needed to prevent and control MERS-CoV infections. In this study, a bacterium (Lactococcus lactis)-like particle (BLP) vaccine displaying the MERS-CoV receptor-binding domain (RBD) was developed, and gram-positive enhancer matrix (GEM) particles were used as substrates to externally bind to the MERS-CoV RBD through a protein anchor (PA). The designs included different numbers of lysin motif (LysM) repeats in the PAs linked by linkers (RBD-linker-PA2 (RLP2), RBD-linker-PA3 (RLP3) and RBD-PA3 (RP3)), and three LysM repeats and a linker in the fusion proteins increased the binding activity to the RBD. The specific immune responses were tested by intranasally immunizing mice with RLP3-GEM with or without the adjuvant GEL01. The results showed that GEL01-adjuvanted RLP3-GEM increased the systemic humoral, cellular and local mucosal immune responses in the mouse model, especially in the intestinal tract. The above results indicate that the MERS-CoV BLP product has the potential to be developed into a promising mucosal candidate vaccine to protect against MERS-CoV infections.

• Publication year

  2019

• Venue

  Viruses

• Publication date

  2019-08-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/v11090799PMID 31470645PMCID 6784119
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection

  2019cited by this paper
• Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.

  2018cited by this paper
• DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice

  2017cited by this paper
• Middle East respiratory syndrome coronavirus (MERS-CoV)

  2017cited by this paper
• Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein

  2017cited by this paper
• Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus

  2017cited by this paper
• Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels

  2017cited by this paper
• Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus

  2017cited by this paper
• Display of recombinant proteins at the surface of lactic acid bacteria: strategies and applications

  2016cited by this paper
• One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus

  2016cited by this paper
• Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

  2016cited by this paper
• An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels

  2016cited by this paper
• MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques

  2016cited by this paper
• Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice

  2016cited by this paper
• Immunogenicity and immunoprotection of porcine circovirus type 2 (PCV2) Cap protein displayed by Lactococcus lactis.

  2016cited by this paper
• 2015 MERS outbreak in Korea: hospital-to-hospital transmission

  2015cited by this paper
• MERS in South Korea and China: a potential outbreak threat?

  2015cited by this paper
• [Comparison of the binding activity of Lactococcus lactis peptidoglycan protein anchor with different number of motifs].

  2015cited by this paper
• A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform

  2015cited by this paper
• A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

  2015cited by this paper
• A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein

  2015cited by this paper
• Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

  2015cited by this paper
• Shigella IpaB and IpaD displayed on L. lactis bacterium-like particles induce protective immunity in adult and infant mice

  2015cited by this paper
• Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

  2015cited by this paper
• Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation.

  2014cited by this paper
• Current advancements and potential strategies in the development of MERS-CoV vaccines

  2014cited by this paper
• Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines

  2014cited by this paper
• The emergence of the Middle East Respiratory Syndrome coronavirus

  2014cited by this paper
• Receptor-binding domain-based subunit vaccines against MERS-CoV

  2014cited by this paper
• Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen

  2014cited by this paper
• Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design

  2014cited by this paper
• The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies

  2013cited by this paper
• Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

  2013cited by this paper
• A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines

  2013cited by this paper
• Fusion protein linkers: property, design and functionality.

  2013cited by this paper
• A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles

  2013cited by this paper
• Hospital outbreak of Middle East respiratory syndrome coronavirus.

  2013cited by this paper
• Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development

  2013cited by this paper
• Efficacy of intranasal and spray delivery of adjuvanted live vaccine against infectious bronchitis virus in experimentally infected poultry

  2012cited by this paper
• Bacterium-like particles as multi-epitope delivery platform for Plasmodium berghei circumsporozoite protein induce complete protection against malaria in mice

  2012cited by this paper
• Microgel particulate adjuvant: characterisation and mechanisms of action

  2010cited by this paper
• Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection

  2009cited by this paper
• LysM, a widely distributed protein motif for binding to (peptido)glycans

  2008cited by this paper
• System Using Tandem Repeats of the cA Peptidoglycan-Binding Domain from Lactococcus lactis for Display of both N- and C-Terminal Fusions on Cell Surfaces of Lactic Acid Bacteria

  2007cited by this paper
• Development of lactococcal GEM-based pneumococcal vaccines.

  2007cited by this paper
• CD69 expression as an index of T-cell function: assay standardization, validation and use in monitoring immune recovery.

  2007cited by this paper
• Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations

  2006cited by this paper
• Novel Surface Display System for Proteins on Non-Genetically Modified Gram-Positive Bacteria

  2006cited by this paper
• Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria.

  2006cited by this paper
• Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral

  2006cited by this paper
• CD69 is an immunoregulatory molecule induced following activation.

  2005cited by this paper
• Divergent Immunoglobulin G Subclass Activity Through Selective Fc Receptor Binding

  2005cited by this paper
• AcmA of Lactococcus lactis is an N‐acetylglucosaminidase with an optimal number of LysM domains for proper functioning

  2005influential reference
• Microbial cell-surface display.

  2003cited by this paper
• The structure of a LysM domain from E. coli membrane-bound lytic murein transglycosylase D (MltD).

  2000cited by this paper
• Demonstration of safety of probiotics -- a review.

  1998cited by this paper

• Robust immunoreaction induced by a subunit vaccine of PEDV spike protein based on GEM surface-display system.

  2026cites this paper
• Gram-positive enhancer matrix delivering FVpE via M cell targeting elicit protective mucosal and adaptive immune responses against Helicobacter pylori infection

  2025cites this paper
• Oral Immunisation With Non‐GMO Surface Displayed SARS‐CoV‐2 Spike Epitopes on Bacteria‐Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice

  2025cites this paper
• Co-injection with inactivated Enterococcus faecium and inactivated H1N1 influenza virus intravenously strengthen the protection of H1N1 influenza virus infections in mice

  2025cites this paper
• Natural peptidoglycan nanoparticles enable rapid antigen purification and potent delivery of plant-derived vaccines

  2025cites this paper
• Redefining Immunization: Recent Advances and Innovations in Vaccine Development

  2025cites this paper
• Immunological Aspects of Mucosal Vaccine-Based Bacterial-like Particles (BLPs) - An updated review.

  2025cites this paper
• A Bacterium-like Particle Vaccine Displaying Envelope Proteins of Canine Distemper Virus Can Induce Immune Responses in Mice and Dogs

  2024cites this paper
• An experimental chimeric hepatitis E virus vaccine elicits both local and systemic immune responses

  2024cites this paper
• A Pool of Bacterium-like Particles Displaying African Swine Fever Virus Antigens Induces Both Humoral and Cellular Immune Responses in Pigs

  2024cites this paper
• A novel bacterium-like particles platform displaying antigens by new anchoring proteins induces efficacious immune responses

  2024cites this paper
• Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.

  2024cites this paper
• An in silico approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

  2024cites this paper
• Development and Immunoprotection of Bacterium-like Particle Vaccine against Infectious Bronchitis in Chickens

  2023cites this paper
• Nano selenium-enriched probiotic Lactobacillus enhances alum adjuvanticity and promotes antigen-specific systemic and mucosal immunity

  2023cites this paper
• Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection

  2023cites this paper
• A Bivalent Bacterium-like Particles-Based Vaccine Induced Potent Immune Responses against the Sudan Virus and Ebola Virus in Mice

  2023cites this paper
• Comparison of Effects of Multiple Adjuvants and Immunization Routes on the Immunogenicity and Protection of HSV-2 gD Subunit Vaccine.

  2023cites this paper
• A Trim-RBD-GEM vaccine candidate protects mice from SARS-CoV-2

  2023cites this paper
• An Attempt of a New Strategy in PRV Prevention: Co-Injection with Inactivated Enterococcus faecium and Inactivated Pseudorabies Virus Intravenously

  2023cites this paper
• Developing an efficient MGCR microneedle nanovaccine patch for eliciting Th 1 cellular response against the SARS-CoV-2 infection

  2023cites this paper
• Bacterium-like particles derived from probiotics: progress, challenges and prospects

  2023cites this paper
• A bacterium-like particle vaccine displaying protective feline herpesvirus 1 antigens can induce an immune response in mice and cats.

  2023cites this paper
• Role of immunobiotic lactic acid bacteria as vaccine adjuvants

  2022cites this paper
• Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to the Coronaviridae and Togaviridae families (Review)

  2022cites this paper
• Application of Nanotechnology in COVID-19 Infection: Findings and Limitations

  2022cites this paper
• Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

  2022cites this paper
• Mucosal Vaccines, Sterilizing Immunity, and the Future of SARS-CoV-2 Virulence

  2022cites this paper
• A novel, non-GMO surface display in Limosilactobacillus fermentum mediated by cell surface hydrolase without anchor motif

  2022cites this paper
• GEM-PA-Based Subunit Vaccines of Crimean Congo Hemorrhagic Fever Induces Systemic Immune Responses in Mice

  2022cites this paper
• The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?

  2022cites this paper
• Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19

  2022cites this paper
• Characteristics of Chimeric West Nile Virus Based on the Japanese Encephalitis Virus SA14-14-2 Backbone

  2021cites this paper
• A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation

  2021cites this paper
• Novel LysM motifs for antigen display on lactobacilli for mucosal immunization

  2021cites this paper
• A bacterium-like particle vaccine displaying Zika virus prM-E induces systemic immune responses in mice

  2021cites this paper
• Analysis of COVID‐19 vaccines: Types, thoughts, and application

  2021cites this paper
• An inactivated recombinant rabies virus displaying the Zika virus prM-E induces protective immunity against both pathogens

  2021cites this paper
• Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice

  2020influential citation
• A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

  2020cites this paper
• An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies

  2020cites this paper
• Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

  2020cites this paper
• A Testimony of the Surgent SARS-CoV-2 in the Immunological Panorama of the Human Host

  2020cites this paper
• COVID-19: Coronavirus Vaccine Development Updates

  2020cites this paper
• A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice

  2019cites this paper